Registry for Peripheral Nerve Stimulation for Pain Management Is Launched
The first registry related to peripheral nerve stimulation (PNS) for pain management is enrolling patients. The registry will collect long-term clinical data with the goal of educating physicians on how a specific neuromodulation device (StimRouter; Bioness, Valencia, CA) can be used for pain management.
The device is approved by the Food and Drug Administration (FDA) for treating chronic pain of peripheral nerve origin, excluding pain in the craniofacial region. It is minimally invasive and consists of a thin, implanted lead with conductive electrode, external pulse transmitter (EPT), and hand-held wireless patient programmer.
When the device is used, electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. The device is programmed by the physician but controlled by the patient to address specific pain-management needs.
The device has been implanted in more than 1,000 chronic pain patients across the US. "The StimRouter Registry is part of a comprehensive initiative to study and develop clinical data relative to peripheral nerve stimulation," said Eric Grigsby, MD, MBA, chief medical officer at Bioness. "We strongly believe that PNS will play a critical role in the management of chronic pain of peripheral nerve origin."